Síndrome de lisis tumoral en neoplasias sólidas: características clínicas y pronóstico

Caravaca-Fontán, Fernando; Martínez-Sáez, Olga; Pampa-Saico, Saúl; Olmedo, María Eugenia; Gomis, Antonio Giner; Garrido, Pilar

doi:10.1016/j.medcli.2016.10.040

Cited by 16 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLS develops during or shortly after the initiation of therapy using glucocorticoids, hormonal agents, or chemotherapeutics such as rituximab [6]. In contrast to hematological neoplasia, solid tumors seldomly present with TLS, and the spontaneous development of the latter is exceptional [7]. Moreover, the prevalence of TLS in solid tumors is difficult to establish because of few published case reports [8].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Spontaneous Tumor Lysis Syndrome in Prostate Cancer

Cabral

Coelho

Fortuna

et al. 2021

Cureus

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is an oncological emergency that most frequently occurs in hematological and high-turnover solid neoplasia. Its incidence in solid, slowly proliferating neoplasia is unclear, primarily because of few published case reports. TLS may be triggered by chemotherapy or infection, or may spontaneously arise. Here, we present a review of the literature and a case of a 58-year-old male patient with prostate cancer who developed spontaneous TLS.

show abstract

Section: Discussionmentioning

confidence: 99%

“…TLS that occurs in patients with solid tumors and spontaneous TLS (STLS) in conjunction with all tumors are associated with increased mortality [7,9]. Most cells proliferate in hematological tumors, and the ensuing large cell mass harbors identical genetic abnormalities, which confer the same theoretical sensitivity to chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Spontaneous Tumor Lysis Syndrome in Prostate Cancer

Cabral

Coelho

Fortuna

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…A recent literature review [1] of published reports of TLS in solid tumours between 1950 and 2014 reported a total of 21 cases of TLS in lung cancer; 13 were of small cell and 8 cases were of non-small cell lung cancer. In another recently published observational retrospective study [2] of all patients with solid tumours diagnosed with TLS over a period of 16 years, a total of 19 patients were identified and only eight had lung cancer.…”

Section: Discussionmentioning

confidence: 99%

“…As a consequence screening is not performed, prophylaxis not given and the diagnosis is delayed or missed with detrimental outcome. TLS is an oncological emergency with mortality of around 15% [9] but in solid tumours including lung cancer where the index of suspicion is low mortality is significantly higher (30–60%) [2]. …”

Section: Discussionmentioning

confidence: 99%

Steroid-induced tumour lysis syndrome in small-cell lung cancer

Khan

Ayub

Mehmood

et al. 2017

Oxford Medical Case Reports

View full text Add to dashboard Cite

A 64-year-old male presented to hospital with breathlessness and weight loss. Ultrasound-guided biopsy of supraclavicular lymph node confirmed a diagnosis of small-cell lung cancer. The patient was started on Dexamethasone 8 mg twice daily for symptom control while awaiting urgent oncology assessment. Three days later he was admitted with acute kidney injury and worsening breathlessness. Biochemical changes confirmed tumour lysis syndrome (TLS) that had occurred following steroid therapy. He was given allopurinol followed by rasburicase. His clinical condition continued to worsen and he died of multi-organ failure. To our knowledge, TLS in small-cell lung cancer solely attributed to steroid therapy has not been described before. Due to its rarity, physicians have a very low index of suspicion of TLS in lung cancer when prescribing corticosteroids for palliation of symptoms. Patients with risk factors should be identified and baseline blood tests performed and appropriate prophylaxis commenced.

show abstract

“…Although elevated serum uric acid has been targeted in cancer in the context of Tumor Lysis Syndrome arising as a side effect of anti-tumor therapies [ 23 ], to date there has been no focus on how a pre-existing background of altered purine metabolism might impact on cancer treatment. In this study, we utilized the PLT2 model to investigate the impact of perturbed purine metabolism on both the tumorigenesis of B16 melanoma and the effectiveness of immune-mediated anti-tumor therapy.…”

Section: Introductionmentioning

confidence: 99%

Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C

et al. 2018

View full text Add to dashboard Cite

Hyperuricaemia is associated with various metabolic dysfunctions including obesity, type 2 diabetes mellitus, hypertension and in general metabolic syndrome, which are all associated with increased risk of cancer. However, the direct association between elevated uricemia and cancer mortality still remains unclear. In this study, we used a mouse model of hyperuricemia, the Urahplt2/plt2 (PLT2) mouse, to investigate the effect of high uric acid levels on anti-tumor immune responses and tumor growth. In normo-uricaemic C57BL/6 mice injected with B16 melanomas, immunotherapy by treatment with Poly I:C at the tumor site delayed tumor growth compared to PBS treatment. In contrast, Poly I:C-treated hyper-uricaemic PLT2 mice were unable to delay tumor growth. Conventional and monocyte-derived dendritic cells in the tumor-draining lymph nodes (dLN) of C57BL/6 and PLT2 mice were similarly increased after Poly I:C immunotherapy, and expressed high levels of CD40 and CD86. CD8+ T cells in the tumor-dLN and tumor of both WT and PLT2 mice were also increased after Poly I:C immunotherapy, and were able to secrete increased IFNγ upon in vitro restimulation. Surprisingly, tumor-specific CD8+ T cells in dLN were less abundant in PLT2 mice compared to C57BL/6, but showed a greater ability to proliferate even in the absence of cognate antigen. These data suggest that hyperuricaemia may affect the functionality of CD8+ T cells in vivo, leading to dysregulated T cell proliferation and impaired anti-tumor activity.

show abstract

Síndrome de lisis tumoral en neoplasias sólidas: características clínicas y pronóstico

Cited by 16 publications

References 8 publications

Spontaneous Tumor Lysis Syndrome in Prostate Cancer

Spontaneous Tumor Lysis Syndrome in Prostate Cancer

Steroid-induced tumour lysis syndrome in small-cell lung cancer

Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C

Contact Info

Product

Resources

About